Paul Scigalla - Oct 18, 2024 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
Chief Medical Officer
Signature
/s/ Sean Ryder, Esq., Attorney-in-Fact
Stock symbol
GNLX
Transactions as of
Oct 18, 2024
Transactions value $
$0
Form type
4
Date filed
10/21/2024, 05:05 PM
Previous filing
Jan 25, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GNLX Stock Option (right to buy) Award $0 +16.7K $0.00 16.7K Oct 18, 2024 Common Stock 16.7K $6.00 Direct F1
transaction GNLX Stock Option (right to buy) Award $0 +16.7K $0.00 16.7K Oct 18, 2024 Common Stock 16.7K $6.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.
F2 100% of the shares subject to the Option shall vest on December 31, 2024.